Written question asked by Lord Taylor of Goss Moor (Liberal Democrat) on Thursday, 26 April 2001, in the House of Commons. It was due for an answer on Tuesday, 8 May 2001. It was answered by Lord Moonie (Labour) on Tuesday, 8 May 2001 on behalf of the Ministry of Defence.

Ministry of Defence

Question: To ask the Secretary of State for Defence, pursuant to his Answer of 25th January, Official Report, 361 c659W, on oripavine, if he will place in the Library details of the evidence which suggests that following single acute doses of TL2636 there are no significant long-term effects on health. - Inc fact that evidence available in the open literature in Library.

Answer: Mr. Matthew Taylor: To ask the Secretary of State for Defence, pursuant to his answer of 25 January 2001, Official Report, column 659W, on Oripavine, if he will place in the Library details of the evidence which suggests that following single acute doses of TL2636 there are no significant long-term effects on health. [159805] Dr. Moonie: I refer the hon. Member to the answer I gave to his previous question. In this response I stated that the Oripavine derivative TL 2636 is a member of the same group of drugs as morphine, and although there had been no long term follow-up studies specifically relating to this derivative, these drugs have been used clinically for many years. The evidence to which I referred is widely available in the open literature and I have placed this in the Library of the House.

Secondary information

Type: Written question
Reference: 368 c23W;368 c15W; 159805
Session: 2000-01
Subjects: Armed forces Chemical and biological warfare Drugs Research Defence Evaluation and Research Agency Clinical trials Oripavine
Link: View this Written question on www.publications.parliament.uk